Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708186 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
A Phase 2 study, sponsored by Axovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02708186 is a Phase 2 study that has completed, run by Axovant Sciences. The registered enrollment target is 34 participants.
The verdict
NCT02708186, a Phase 2 study, has completed, sponsored by Axovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD).
Interventions
- DRUG Placebo
- DRUG Nelotanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02708186
The ClinicalTrials.gov registry entry for NCT02708186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axovant Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02708186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02708186 about?
NCT02708186 is a clinical study titled "Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)". This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD).
What is the current status of trial NCT02708186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-03. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02708186?
The interventions under investigation include: Placebo (DRUG), Nelotanserin (DRUG).
Who is sponsoring clinical trial NCT02708186?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.